跳至主要内容
临床试验/NCT01348828
NCT01348828已完成不适用

Prospective, Multicenter, Single Arm Feasibility and Safety Study of the Endologix Fenestrated Stent Graft System for the Endovascular Repair of Juxtarenal/Pararenal (JAA/PAA) Aneurysms

Endologix8 个研究点 分布在 6 个国家目标入组 49 人开始时间: 2011年10月19日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
Endologix
入组人数
49
试验地点
8
主要终点
Primary Safety Endpoint

研究概览

简要总结

The aim of this study is to evaluate the safety and feasibility of the Endologix Fenestrated Stent Graft System for the endovascular repair of juxtarenal or pararenal aortic aneurysms.

详细描述

The Endologix Fenestrated Stent Graft System that will be used in this study has three components, listed below:

  1. Endologix unibody bifurcated stent graft
  2. Endologix fenestrated proximal extension stent graft
  3. Endologix renal stent graft

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Adequate iliac/femoral access compatible with the required delivery systems
  • •Non-aneurysmal infrarenal aortic neck <15mm in length
  • •Most caudal renal artery to aortoiliac bifurcation length >= 70
  • •SMA to aortoiliac bifurcation length >=90mm
  • •Proximal non-aneurysmal aortic neck below the SMA with diameter 18 to 34 mm, length >=15mm and angle <=60° to the aneurysm sac
  • •Angle <=60° (clock face) between the SMA and CA
  • •Renal arteries both at or below the SMA by <=35mm and within 30mm of each other axially, with 4 to 8mm lumen diameter, and with clockface angle of 90° to 210° to each other
  • •Common iliac artery distal fixation site with: distal fixation length >=15mm, with diameter >=10 mm and <=23 mm and angle <=90° to the aortic bifurcation
  • •Ability to preserve at least one hypogastric artery

排除标准

  • •Life expectancy <2 years as judged by the investigator
  • •Psychiatric or other condition that may interfere with the study
  • •Participating in the enrollment or 30-day follow-up phase of another clinical study
  • •Known allergy to any device component
  • •Coagulopathy or uncontrolled bleeding disorder
  • •Contraindication to contrast media or anticoagulants
  • •Ruptured, leaking, or mycotic aneurysm
  • •Aortic dissection Serum creatinine (S-Cr) level >2.0 mg/dL
  • •Traumatic vascular injury
  • •Active systemic or localized groin infection
  • •Connective tissue disease (e.g., Marfan's Syndrome)
  • •Recent(within prior three months)cerebrovascular accident
  • •Recent(within prior three months)myocardial infarction
  • •Prior renal transplant
  • •Length of either renal artery to be stented <12mm
  • •Significant occlusive disease or calcification of either renal artery (>70%)
  • •An essential accessory renal artery
  • •Indispensable inferior mesenteric artery
  • •Untreated aneurysmal disease of the descending thoracic aorta
  • •Clinically significant mural thrombus circumferentially in the suprarenal segment
  • •Prior iliac artery stent implanted that may interfere with delivery system introduction
  • •Unsuitable vascular anatomy
  • •Pregnancy

研究组 & 干预措施

Single Arm

Other

All patients meet study criteria receives a single use Ventana Fenestrated System, which requires administration of intravascular contrast. Catheter advancement is performed under fluoroscopic guidance and Ventana Fenestrated System is placed.

干预措施: Endovascular Aortic Aneurysm Repair (Endologix Fenestrated Stent Graft System) (Device)

结局指标

主要结局

Primary Safety Endpoint

时间窗: 30 days

Major adverse events defined as: * All-cause death * Bowel ischemia * Myocardial infarction * Paraplegia * Renal failure * Respiratory failure * Stroke * Blood loss \>=1,000cc

次要结局

  • Mortality(Procedurally and to 5 Years)
  • Feasibility/Effectiveness(1 Year)
  • Stent Graft Patency(30 Days, 6 Months, and Years 1 to 5)
  • Major Adverse Events(>30 Days to 5 Years)
  • Number of Participants With Renal Dysfunction(30 Days, 6 Months and Years 1 to 5)
  • Aneurysm Rupture(Procedurally and to 5 Years)
  • Device Integrity(30 Days, 6 Months, and Years 1 to 5)
  • Aneurysm Diameter Change(6 Months, and Years 1 to 5)
  • Procedural/In-hospital Evaluations(Discharge)
  • Secondary Procedures(30 Days, 6 Month and Years 1 to 5)
  • Conversion to Open Repair(Procedurally and to 5 Years)
  • Procedural/In-hospital Evaluations(Procedurally and to hospital discharge)

研究者

发起方
Endologix
申办方类型
Industry
责任方
Sponsor

研究点 (8)

Loading locations...

相似试验